CN103446091A - Incarviatone A在治疗喉癌药物中的应用 - Google Patents
Incarviatone A在治疗喉癌药物中的应用 Download PDFInfo
- Publication number
- CN103446091A CN103446091A CN2013104322160A CN201310432216A CN103446091A CN 103446091 A CN103446091 A CN 103446091A CN 2013104322160 A CN2013104322160 A CN 2013104322160A CN 201310432216 A CN201310432216 A CN 201310432216A CN 103446091 A CN103446091 A CN 103446091A
- Authority
- CN
- China
- Prior art keywords
- incarviatone
- laryngeal cancer
- application
- preparation
- cancer treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 206010023825 Laryngeal cancer Diseases 0.000 title abstract description 12
- 206010023841 laryngeal neoplasm Diseases 0.000 title abstract description 12
- 229940079593 drug Drugs 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 17
- 201000005264 laryngeal carcinoma Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 abstract 2
- 239000003560 cancer drug Substances 0.000 abstract 1
- 230000000459 effect on growth Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000012010 growth Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001121991 Incarvillea delavayi Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010043966 Tongue neoplasm malignant stage unspecified Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000025358 tongue carcinoma Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了Incarviatone A在制备治疗喉癌药物中的应用，属于药物新用途技术领域。本发明通过体外MTT抗肿瘤活性评价发现，Incarviatone A对人喉癌细胞株HEP-2、TU686、M2e和M4e的生长也具有显著的抑制作用。因此，Incarviatone A能用于制备抗喉癌药物，具有良好的开发应用前景。对于本发明涉及的Incarviatone A在制备治疗喉癌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于喉癌细胞的抑制活性强得意想不到。
Description
技术领域
本发明涉及化合物Incarviatone A的新用途，尤其涉及Incarviatone A在制备抗喉癌药物中的应用。
技术背景
癌症是对人类生命健康危害最大的疾病之一，每年都有大量的人死于癌症。抗癌药物的研发一直是药学研究的热点。抗肿瘤药物中有74%是天然产物或其衍生物，如紫杉醇及其衍生物就是目前临床上应用效果比较好的抗肿瘤药物。因此，从天然产物中寻找抗癌化合物或先导化合物具有重要的意义。
本发明涉及的化合物Incarviatone A是一个2012年发表（Shen,Y.H.et al.,2012.Incarviatone A,a structurally unique natural product hybrid with a new carbonskeleton from Incarvillea delavayi,and its absolute configuration via calculatedelectronic circular dichroic spectra.RSC Advances2,4175–4180.）的新骨架化合物，该化合物拥有全新的骨架类型，目前没有关于该化合物活性方面的报道，对于本发明涉及的在制备治疗喉癌药物中的用途属于首次公开，而且由于骨架类型属于全新的骨架类型，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于喉癌的防治显然具有显著的进步。
发明内容
本发明提供化合物Incarviatone A在制备抗肿瘤药物中的应用。
本发明采用如下技术方案：Incarviatone A在制备抗喉癌药物中的应用，Incarviatone A的结构式如式（Ⅰ）所示：
本发明通过体外MTT抗肿瘤活性评价发现，Incarviatone A对人喉癌细胞株HEP-2、TU686、M2e和M4e的生长也具有显著的抑制作用，抑制这4株细胞生长的IC50值分别为0.77±0.09μM、0.12±0.03μM、0.79±0.11μM和1.19±0.15μM。因此，Incarviatone A能用于制备抗喉癌药物，具有良好的开发应用前景。
本发明涉及的Incarviatone A在制备治疗舌癌药物中的用途属于首次公开，由于骨架类型属于全新的骨架类型，而且其对于舌癌细胞的抑制活性强得意想不到，不存在由其他化合物给出任何启示的可能，具备突出的实质性特点，同时用于舌癌的防治显然具有显著的进步。
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
具体实施方式
本发明所涉及化合物Incarviatone A的制备方法参见文献（Shen,Y.H.et al.,2012.Incarviatone A,a structurally unique natural product hybrid with a new carbon skeleton from Incarvilleadelavayi,and its absolute configuration via calculated electronic circular dichroic spectra.RSC Advances2,4175–4180.）。
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
实施例1：本发明所涉及化合物Incarviatone A片剂的制备：
取20克化合物Incarviatone A，加入制备片剂的常规辅料180克，混匀，常规压片机制成1000片。
实施例2：本发明所涉及化合物Incarviatone A胶囊剂的制备：
取20克化合物Incarviatone A，加入制备胶囊剂的常规辅料如淀粉180克，混匀，装胶囊制成1000片。
下面通过药效学实验来进一步说明其药物活性。
实验例：采用MTT法评价化合物Incarviatone A对人喉癌细胞株的生长抑制作用
1.方法：处于生长对数期的细胞：人喉癌细胞株HEP-2、TU686、M2e和M4e（购买自中国科学院细胞库）以1.5×104浓度种于96孔板中。细胞培养24h贴壁后吸去原来的培养基。试验分为空白对照组、药物处理组。空白组更换含10%胎牛血清的1640培养基；药物处理组更换含浓度为100μM，50μM，10μM，1μM，0.1μM，0.01μM和0.001μM的Incarviatone A的培养基。培养48h后，加入浓度5mg/mL的MTT，继续放于CO2培养箱培养4h，然后沿着培养液上部吸去100μL上清，加入100μL DMSO，暗处放置10min，利用酶标仪（Sunrise公司产品）测定吸光值(波长570nm)，并根据吸光值计算细胞存活情况，每个处理设6个重复孔。细胞存活率(%)=ΔOD药物处理/ΔOD空白对照×100。
2.结果：Incarviatone A对人喉癌细胞株HEP-2、TU686、M2e和M4e的生长具有显著的抑制作用。该化合物抑制人喉癌细胞株HEP-2、TU686、M2e和M4e生长的IC50值分别为：0.77±0.09μM、0.12±0.03μM、0.79±0.11μM和1.19±0.15μM。
由上述实施例表明，本发明的Incarviatone A对人喉癌细胞株HEP-2、TU686、M2e和M4e的生长具有很好的抑制作用。由此证明，本发明的Incarviatone A具有抗喉癌活性，能用于制备抗喉癌药物。
Claims (1)
1.Incarviatone A在治疗喉癌药物中的应用，所述化合物Incarviatone A结构如式（Ⅰ）所示：
式（Ⅰ）。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310432216.0A CN103446091B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备治疗喉癌药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310432216.0A CN103446091B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备治疗喉癌药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103446091A true CN103446091A (zh) | 2013-12-18 |
| CN103446091B CN103446091B (zh) | 2015-11-25 |
Family
ID=49729213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310432216.0A Expired - Fee Related CN103446091B (zh) | 2013-09-22 | 2013-09-22 | Incarviatone A在制备治疗喉癌药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103446091B (zh) |
-
2013
- 2013-09-22 CN CN201310432216.0A patent/CN103446091B/zh not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| YUN-HENG SHEN等: "Incarviatone A, a structurally unique natural product hybrid with a new carbon skeleton from Incarvillea delavayi, and its absolute configuration calculated electronic circular dichroic spectra{", 《RSC ADV》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103446091B (zh) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103462960A (zh) | Incarviatone A在治疗前列腺癌药物中的应用 | |
| CN103405418A (zh) | Chukrasone B在治疗乳腺癌药物中的应用 | |
| CN103127091A (zh) | Aphanamixoid A在治疗结直肠癌药物中的应用 | |
| CN103446091A (zh) | Incarviatone A在治疗喉癌药物中的应用 | |
| CN103316008A (zh) | Aspeverin在制备治疗直肠癌药物中的应用 | |
| CN103446086A (zh) | Incarviatone A在治疗胃癌药物中的应用 | |
| CN103446089A (zh) | Incarviatone A在治疗鼻咽癌药物中的应用 | |
| CN103446088A (zh) | Incarviatone A在治疗皮肤癌药物中的应用 | |
| CN103446092A (zh) | Incarviatone A在治疗宫颈癌药物中的应用 | |
| CN103446084A (zh) | Incarviatone A在治疗胰腺癌药物中的应用 | |
| CN103446087A (zh) | Incarviatone A在治疗子宫内膜癌药物中的应用 | |
| CN103462969A (zh) | Incarviatone A在治疗乳腺癌药物中的应用 | |
| CN103462958A (zh) | Incarviatone A在治疗舌癌药物中的应用 | |
| CN103462974A (zh) | Incarviatone A在治疗卵巢癌药物中的应用 | |
| CN103462961A (zh) | Incarviatone A在治疗膀胱癌药物中的应用 | |
| CN103405452A (zh) | Chukrasone A在治疗胃癌药物中的应用 | |
| CN103462971A (zh) | Incarviatone A在治疗肾癌药物中的应用 | |
| CN103462959A (zh) | Incarviatone A在治疗肝癌药物中的应用 | |
| CN103393652A (zh) | Sarcaboside A在治疗喉癌药物中的应用 | |
| CN103405412A (zh) | Chukrasone B在治疗喉癌药物中的应用 | |
| CN103446143A (zh) | Lycojaponicumin C在治疗胃癌药物中的应用 | |
| CN103462966A (zh) | Incarviatone A在治疗结直肠癌药物中的应用 | |
| CN103462964A (zh) | Incarviatone A在治疗胆管癌药物中的应用 | |
| CN103446133A (zh) | Lycojaponicumin B在治疗舌癌药物中的应用 | |
| CN103405451A (zh) | Chukrasone A在治疗舌癌药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151027 Address after: 266000 Shandong province Qingdao city Licang District Road No. 1020 Laoshan two unit 302 Applicant after: Li Shulan Address before: Metro Technology Building No. 69 Olympic Avenue in Jianye District of Nanjing city in Jiangsu province 210019 01 5 storey buildings Applicant before: Nanjing Guangkangxie Biomedical Technology Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 225327 Taizhou, Jiangsu, Jiangsu Province, Yongan Town, North Yongan Road, No. 203 Patentee after: Li Shulan Address before: 266000 Shandong province Qingdao city Licang District Road No. 1020 Laoshan two unit 302 Patentee before: Li Shulan |
|
| CB03 | Change of inventor or designer information |
Inventor after: Zhao Xinying Inventor after: Gao Yifang Inventor after: Dong Ran Inventor before: Jiang Chunping Inventor before: Huang Rong |
|
| CB03 | Change of inventor or designer information | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170322 Address after: 071000 Baoding City, Hebei Province, south of the city built a new building in the main street A block No. 1201 Patentee after: Zhao Xinying Patentee after: Gao Yifang Patentee after: Dong Ran Address before: 225327 Taizhou, Jiangsu, Jiangsu Province, Yongan Town, North Yongan Road, No. 203 Patentee before: Li Shulan |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 Termination date: 20170922 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |